Advertisement
Product › Details
gene therapy
Next higher product group | BIOTECH | |
Record changed: 2024-04-06 |
Advertisement
More documents for gene therapy
- [1] Asgard Therapeutics AB. (3/14/24). "Press Release: Asgard Therapeutics Announces €30 Million Series A Financing to Advance Its First-in-Class in vivo Cell Reprogramming Platform for Immuno-oncology". Lund....
- [2] Sensorion S.A.. (2/9/24). "Press Release: Sensorion Announces a €50.5 Million Financing with Participation from New and Existing US and European Healthcare Specialist Investors [ not for US, et al.; only for qualified persons]". Montpellier....
- [3] GenSight Biologics S.A.. (2/8/24). "Press Release: GenSight Biologics Announces Completion of a €5 million capital Increase with Sofinnova Partners, Invus, UPMC Enterprises and Heights Capital". Paris....
- [4] ReiThera S.r.l.. (1/22/24). "Press Release: ReiThera Srl, the Ragon Institute and IAVI Announce Collaboration to Advance Highly Networked T Cell HIV Vaccine Candidate Towards Phase I Clinical Evaluation". Rome & Cambridge, MA....
- [5] Sensorion S.A.. (1/19/24). "Press Release: Sensorion Announces Approval to Initiate Lead Gene Therapy Candidate SENS-501 (OTOF-GT) into a Phase 1/2 Clinical Trial in some European Countries". Montpellier....
- [6] Sensorion S.A.. (1/5/24). "Press Release: Sensorion Announces Partnership with the Institut Pasteur to Accelerate Gene Therapy Programs Targeting Hearing Disorders Has Been Extended for Five Years". Montpellier....
- [7] GenSight Biologics S.A.. (12/22/23). "Press Release: GenSight Biologics Appoints Laurence Rodriguez as Chief Executive Officer". Paris....
- [8] Freeline Therapeutics Holdings plc. (11/22/23). "Press Release: Syncona to Acquire Freeline Therapeutics". London....
- [9] GenSight Biologics S.A.. (11/21/23). "Press Release: GenSight Biologics Announces a Successful Offering for an Amount of approximately €4.7 Million". Paris....
- [10] GenSight Biologics S.A.. (11/20/23). "Press Release: GenSight Biologics Announces Launch of an Offering for an Indicative Amount of €5 Million that Has Received Subscription Commitments from New and Existing Shareholders Totaling €4 Million". Paris....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top